Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by Biotech777on Dec 18, 2011 2:50pm

393 Views

Post# 19333032

RE: RE: RE: RE: RE: RE: RE: RE: Biotech 777..FYI

I think this is why there is so much interest in HDL based therapies and the logical motivation for pairing with a statin (besides big pharma).As far as very early intervention, I think this is why Abbott has gotten into the branded neutraceuticals with Niaspan as there seems to be good reason for taking early in life.

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity